Subsequent COVID-19 Prophylaxis in COVID-19 Associated Glomerulopathies
Successful vaccination has been the decisive factor in the overall decline of SARS-CoV2 infection related morbidity and mortality. However, global effects of the COVID-19 pandemic are ongoing, with reports of glomerular disease occurring in relation to both infection and vaccination. A particular ri...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-06-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/11/7/1152 |
| _version_ | 1827731583199608832 |
|---|---|
| author | Therese Boyle Emma O’Lone Elaine Phua Janet Anderson Amanda Mather Suran L. Fernando |
| author_facet | Therese Boyle Emma O’Lone Elaine Phua Janet Anderson Amanda Mather Suran L. Fernando |
| author_sort | Therese Boyle |
| collection | DOAJ |
| description | Successful vaccination has been the decisive factor in the overall decline of SARS-CoV2 infection related morbidity and mortality. However, global effects of the COVID-19 pandemic are ongoing, with reports of glomerular disease occurring in relation to both infection and vaccination. A particular rise in anti-GBM disease has been identified. Information is still emerging regarding the optimal management of such cases. We reviewed anti-GBM antibody detection rates at our test center over the past 5 years. We followed three patients with biopsy confirmed glomerular disease temporally related to COVID-19 vaccination. Each patient proceeded to receive subsequent COVID-19 vaccination as per immunologist recommendations. Further assessment included COVID-19 antibody testing in each case. A three-fold increase in significant anti-GBM antibody results noted at our center was associated with COVID infection in 10% of cases, and COVID vaccination in 25% of cases. We demonstrated that subsequent vaccination did not appear to lead to adverse effects including relapse in our three cases of COVID-19 vaccine-associated GN. We also identified positive COVID-19 antibody levels in two out of three cases, despite immunosuppression. We report a rise in anti-GBM antibody disease incidence. Our small study suggests that COVID-19 antibody testing can help determine COVID prophylaxis requirements, and subsequent vaccination with an alternative vaccine type appears safe. |
| first_indexed | 2024-03-11T00:35:09Z |
| format | Article |
| id | doaj.art-58d5a21b19b14e1594aec5d707af7fe3 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-11T00:35:09Z |
| publishDate | 2023-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-58d5a21b19b14e1594aec5d707af7fe32023-11-18T21:40:22ZengMDPI AGVaccines2076-393X2023-06-01117115210.3390/vaccines11071152Subsequent COVID-19 Prophylaxis in COVID-19 Associated GlomerulopathiesTherese Boyle0Emma O’Lone1Elaine Phua2Janet Anderson3Amanda Mather4Suran L. Fernando5Department of Clinical Immunology and Allergy, Royal North Shore Hospital, St Leonards, Sydney, NSW 2065, AustraliaFaculty of Medicine and Health, University of Sydney, Camperdown, Sydney, NSW 2050, AustraliaDepartment of Renal Medicine, Royal North Shore Hospital, St Leonards, Sydney, NSW 2065, AustraliaImmunology Laboratory, Royal North Shore Hospital, St Leonards, Sydney, NSW 2065, AustraliaFaculty of Medicine and Health, University of Sydney, Camperdown, Sydney, NSW 2050, AustraliaDepartment of Clinical Immunology and Allergy, Royal North Shore Hospital, St Leonards, Sydney, NSW 2065, AustraliaSuccessful vaccination has been the decisive factor in the overall decline of SARS-CoV2 infection related morbidity and mortality. However, global effects of the COVID-19 pandemic are ongoing, with reports of glomerular disease occurring in relation to both infection and vaccination. A particular rise in anti-GBM disease has been identified. Information is still emerging regarding the optimal management of such cases. We reviewed anti-GBM antibody detection rates at our test center over the past 5 years. We followed three patients with biopsy confirmed glomerular disease temporally related to COVID-19 vaccination. Each patient proceeded to receive subsequent COVID-19 vaccination as per immunologist recommendations. Further assessment included COVID-19 antibody testing in each case. A three-fold increase in significant anti-GBM antibody results noted at our center was associated with COVID infection in 10% of cases, and COVID vaccination in 25% of cases. We demonstrated that subsequent vaccination did not appear to lead to adverse effects including relapse in our three cases of COVID-19 vaccine-associated GN. We also identified positive COVID-19 antibody levels in two out of three cases, despite immunosuppression. We report a rise in anti-GBM antibody disease incidence. Our small study suggests that COVID-19 antibody testing can help determine COVID prophylaxis requirements, and subsequent vaccination with an alternative vaccine type appears safe.https://www.mdpi.com/2076-393X/11/7/1152anti-GBM diseaseANCA-associated vasculitisCOVID-19vaccinationantibodies |
| spellingShingle | Therese Boyle Emma O’Lone Elaine Phua Janet Anderson Amanda Mather Suran L. Fernando Subsequent COVID-19 Prophylaxis in COVID-19 Associated Glomerulopathies Vaccines anti-GBM disease ANCA-associated vasculitis COVID-19 vaccination antibodies |
| title | Subsequent COVID-19 Prophylaxis in COVID-19 Associated Glomerulopathies |
| title_full | Subsequent COVID-19 Prophylaxis in COVID-19 Associated Glomerulopathies |
| title_fullStr | Subsequent COVID-19 Prophylaxis in COVID-19 Associated Glomerulopathies |
| title_full_unstemmed | Subsequent COVID-19 Prophylaxis in COVID-19 Associated Glomerulopathies |
| title_short | Subsequent COVID-19 Prophylaxis in COVID-19 Associated Glomerulopathies |
| title_sort | subsequent covid 19 prophylaxis in covid 19 associated glomerulopathies |
| topic | anti-GBM disease ANCA-associated vasculitis COVID-19 vaccination antibodies |
| url | https://www.mdpi.com/2076-393X/11/7/1152 |
| work_keys_str_mv | AT thereseboyle subsequentcovid19prophylaxisincovid19associatedglomerulopathies AT emmaolone subsequentcovid19prophylaxisincovid19associatedglomerulopathies AT elainephua subsequentcovid19prophylaxisincovid19associatedglomerulopathies AT janetanderson subsequentcovid19prophylaxisincovid19associatedglomerulopathies AT amandamather subsequentcovid19prophylaxisincovid19associatedglomerulopathies AT suranlfernando subsequentcovid19prophylaxisincovid19associatedglomerulopathies |